Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma me

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma me

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma me

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma me

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical

Guest: Qi Cui, MD, PhD First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma me

Guest: Davinder S. Grover, MD, MPH First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical

Host: Vallerie V. McLaughlin, MD Guest: Rajan Saggar, MD Diagnosis of pulmonary arterial hypertension, or PAH, may be delayed because symptoms are nonspecific. And while there have been many advances in terms of available treatments, it rema